FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT in Adult and Paediatric Patients with AML or MDS By Ogkologos - March 13, 2025 811 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MC-FludT.14/L Trial II Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Lung cancer screening can’t leave anyone in the UK behind July 27, 2023 The 10 Things That Helped Me Cope With My 2 Cancer... February 6, 2024 Opioid Use Drops Among Cancer Patients at End of Life August 20, 2021 FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a... December 10, 2024 Load more HOT NEWS ESMO Welcomes Draft Report on Europe’s Beating Cancer Plan (BCP) Which... Protecting Your Skin From the Sun All Year: Why It’s Important... 7 Practical Tips for Taking Long-Term Medication Cancer Survivor with Strong Family History Was Denied Regular Screening Because...
